Acadia Pharmaceuticals (ACAD) Shares Outstanding (2010 - 2026)

Acadia Pharmaceuticals has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $172.1 million in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 2.09% year-over-year to $172.1 million in Q2 2026; TTM through Jun 2026 was $172.1 million, a 2.09% increase from a year earlier, with the FY2025 full-year figure at $170.3 million, up 2.16% from the prior year.
• Shares Outstanding (Entity) was $172.1 million for Q2 2026 at Acadia Pharmaceuticals, up from $171.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $172.1 million in Q2 2026, with the low at $161.4 million in Q1 2022.
• Average Shares Outstanding (Entity) over 5 years is $165.8 million, with a median of $165.4 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) increased 0.62% in 2023, then increased 2.38% in 2026.
• Over 5 years, Shares Outstanding (Entity) stood at $162.1 million in 2022, then advanced by 1.6% to $164.7 million in 2023, then advanced by 1.25% to $166.7 million in 2024, then gained by 2.16% to $170.3 million in 2025, then gained by 1.07% to $172.1 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $172.1 million (Q2 2026), $171.1 million (Q1 2026), and $170.3 million (Q4 2025), per Business Quant data.